

EXHIBIT 6



November 11, 2004

Department of Public Health and Human Services
Attn: State Pharmacy Manager
1400 Broadway
P.O. Box 202951
Helena, MT 59620

Re: 3Q04 Average Sales Price
Labelers 00186 and 00310

RECEIVED
NOV 16 2004
CHILD & ADULT
HEALTH RESOURCES

In accordance with Section III (D)(2) of the June 2003 Corporate Integrity Agreement between AstraZeneca Pharmaceuticals LP and the Office of Inspector General (OIG), enclosed are the 3rd Quarter 2004 Average Sales Prices for Covered Products identified in Appendix A of the CIA along with a description of the methodology used to calculate the Average Sales Price and Requisite Certification.

In an effort to keep our files current, we are requesting that you email any address changes and your contact person's telephone number (for Fed Ex deliveries) to:

Cindy.Salfrank@astrazeneca.com

If you have any questions or concerns relating to these Average Sales Prices, please contact Cindy Salfrank at (302) 886-5287 or myself at (302) 886-2268 and we will provide further details.

Sincerely,

A handwritten signature in black ink, appearing to read "E. L. Selvaggi".

Esther L. Selvaggi, CPA
Senior Manager, Government Pricing and Analytics
AstraZeneca Government Contract Operations

Enclosures (3)

MT 038697

Managed Markets Business Group

AstraZeneca LP

1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437

www.astrazeneca-us.com

8/11/2004

3Q04 ASP Data**Labelers 00186 and 00310**

NDC	ASP
00186011001	0.086563
00186011201	0.217319
00186011291	0.189330
00186011401	0.254951
00186011412	0.428008
00186011491	0.238964
00186011501	0.092861
00186011512	0.182013
00186011701	0.267494
00186011712	0.416913
00186011791	0.287043
00186011801	0.000000
00186011891	0.000000
00186012001	0.105630
00186012201	0.463373
00186012212	0.501050
00186012213	0.000000
00186012291	0.453346
00186012501	0.110723
00186012512	0.000000
00186013501	0.067238
00186013701	0.146896
00186014001	0.076924
00186014501	0.068487
00186015001	0.083985
00186015501	0.085261
00186016001	0.090130
00186016601	0.036400
00186016801	0.000000
00186016901	0.000000
00186021003	0.651312
00186021203	3.807620
00186021503	0.849306
00186022503	0.000000
00186023003	0.363082
00186023203	0.491451
00186024002	0.000000
00186024012	0.000000
00186024044	4.603363
00186024113	0.932003
00186024213	0.335095
00186024312	0.178684
00186024412	0.000000
00186024444	4.260182
00186024502	0.000000
00186024554	6.629582
00186025002	0.443483
00186025502	0.244385
00186025592	0.000000
00186026002	0.253767
00186026092	0.222839
00186026502	0.276422

MT 038698

8/11/2004

3Q04 ASP Data**Labelers 00186 and 00310**

NDC	ASP
00186026503	0.319828
00186027512	0.152807
00186027613	0.590903
00186027713	0.338101
00186027812	0.000000
00186027844	3.765645
00186027854	5.383066
00186190501	0.250821
00186190601	0.246977
00310004910	0.000000
00310010810	0.690886
00310032111	0.000000
00310032115	0.000000
00310032130	28.609909
00310032511	0.000000
00310032515	12.775900
00310032520	13.960914
00310037510	93.929683
00310037561	6.831386
00310037610	4.685271
00310037611	0.000000
00310037631	9.815421
00310037633	0.000000
00310037634	0.000000
00310037660	7.811979
00310037720	18.256348
00310037721	0.000000
00310037732	18.928206
00310037733	0.000000
00310037734	0.000000
00310037762	4.205903
00310037851	9.859923
00310037951	19.691096
00310072025	150.855201
00310072050	151.854311
00310095036	189.598855
00310095130	269.810273
00310096036	0.000000
00310096130	0.000000
00310328610	0.000000


MT 038699

EXHIBIT 'A' CERTIFICATION FORM

CERTIFICATION

The undersigned, an agent of AstraZeneca Pharmaceuticals LP, hereby certifies that the attached average sale price information has been communicated to First Databank or any successor or alternative reporting agency, and that it has been calculated in accordance with the methodology described in the State Settlement Agreement and as further described in AstraZeneca Pharmaceuticals LP's Corporate Integrity Agreement with the Office of Inspector General of the United States Department of Health and Human Services.

Signed


Esther L. Selvaggi, C.P.A.

Title Senior Manager, Government Pricing and Analytics

Date

11/11/2004

MT 038700

AstraZeneca PharmaceuticalsCIA Average Sale Price Methodology**Appendix A: Corporate Integrity Agreement (CIA) Average Sale Price Calculation Methodology**
Average Sale Price =

$$\frac{(\text{Accounts Receivable \$} - \text{Chargeback Sales \$} - \text{Chargeback Discounts \$} - \text{Managed Care Discounts \$})}{(\text{Accounts Receivable Units} - \text{Chargeback Sales Units})}$$

Accounts Receivable \$ =**(Total Direct Sales \$ + Adjustments to Total Direct Sales \$ - Early Pay Discount \$ - SBC Direct Purchase Admin Fees)**

- **Total Direct Sales \$:** All direct sales \$ from all Trade Classes & Market Segments as identified by the "Market Segment to Government Pricing Mapping" report. This value is for a calendar quarter, with the **Invoice Date** determining if a direct sale participates in this quarter's calculation. The majority of the direct sales are to wholesalers, retailers, and mail-order. Returns in the normal course of business are excluded. U.S. Territories Sales are excluded. Direct Federal & PHS/DSH sales are excluded.
- **Adjustments to Total Direct Sales \$:** All direct sales adjustment \$ from all Trade Classes & Market Segments as identified by the "Market Segment to Government Pricing Mapping" report. This value is for a calendar quarter, with the **Invoice Date** determining if a direct adjustment participates in this quarter's calculation. The majority of the direct adjustments are to wholesalers, retailers, and mail-order. Adjustments to Returns in the normal course of business are excluded. Direct Federal & PHS/DSH adjustments are excluded. U.S. Territories Sales adjustments are excluded.
- **Early Pay Discount \$:** early pay discount for Total Direct Sales \$. The discount is calculated individually for each direct sale, but is usually 2%.
- **SBC Direct Purchase Admin Fees:** Fee \$ are earned on direct purchases from Sales-based contracts. The fee is attached to the SBC contract. Payments are made to the contract owner via check. These accounts are typically commercial buying groups. They are a flat % across all products and sales on the contract. This value is for a calendar quarter, with the admin fee **Date Paid** determining if a fee participates in this quarter's calculation. If a sale is excluded from the ASP calculation, then the fee/rebate \$ associated with this sale must also be excluded.

AstraZeneca PharmaceuticalsCIA Average Sale Price Methodology

Accounts Receivable Units = All direct sales units from all Trade Classes & Market Segments as identified by the "Market Segment to Government Pricing Mapping" report. This value is for a calendar quarter, with the **Invoice Date** determining if a direct sale participates in this quarter's calculation. Returns in the normal course of business are excluded. U.S. Territories Sales are excluded. Direct Federal & PHS/DSH sales are excluded. (Note: The Units UOM is the Medicaid UOM.)

Chargeback Sales \$ = 0.98 * (Chargeback Sales @ WAC \$)

- **Chargeback Sales @ WAC \$:** All chargeback (indirect) sales \$ to the Federal Government, including PHS/DSH. Can be from any Federal contract, including but not limited to the FSS, BPAs, national contracts, and the PHS/DSH contracts. Each sale is priced at the WAC in effect as of the sale's invoice date. This value is for a calendar quarter, with the **CB Date Received** determining if a sale participates in this quarter's calculation. Returns in the normal course of business are excluded. U.S. Territories Sales are excluded.
- **Chargeback Sales Units** = All chargeback (indirect) sales units to the Federal Government, including PHS/DSH. Can be from any Federal contract, including but not limited to the FSS, BPAs, national contracts, and the PHS/DSH contracts. This value is for a calendar quarter, with the **CB Date Received (or Date Paid)** determining if a sale participates in this quarter's calculation. Returns in the normal course of business are excluded. U.S. Territories Sales are excluded.

MT 038702

AstraZeneca PharmaceuticalsCIA Average Sale Price Methodology**Chargeback Discounts \$ =****(Total Commercial CB Credit \$ + SBC Indirect Purchase Admin Fee \$ + Non-Invoice Price Adjustment \$)**

- **Total Commercial CB Credit \$:** Chargeback credit \$ from all market segments that are not Federal, PHS, or Covered Entities. These customers are typically institutions. This value is for a calendar quarter, with the **CB Date Received** determining if a sale participates in this quarter's calculation. Returns in the normal course of business are excluded. U.S. Territories Sales are excluded.
- **SBC Indirect Purchase Admin Fee \$:** Fee \$ are earned on indirect purchases from Sales-based contracts. The fee is attached to the SBC contract. Payments are made to the contract owner via check. These accounts are typically commercial buying groups. They are a flat % across all products and sales on the contract. This value is for a calendar quarter, with the admin fee **Date Paid** determining if a fee participates in this quarter's calculation. If a sale is excluded from the ASP calculation, then the fee/rebate \$ associated with this sale must also be excluded.
- **Non-Invoice Price Adjustment \$:** Adjustment \$ paid to institutional customers when the contracted product is not available for purchase and a substitute product is purchased. Adjustment \$ from all market segments that are not Federal, PHS, or Covered Entities. These customers are typically institutions. This value is for a calendar quarter, with the **Invoice Date** determining if an adjustment participates in this quarter's calculation.

MT 038703

AstraZeneca PharmaceuticalsCIA Average Sale Price Methodology**Managed Care Discounts \$ =****(SBC Performance Fee \$ + SBC Rebate \$ + UBC Admin Fee \$ + UBC Performance Fee \$ + UBC Rebate \$)**

- **SBC Performance Fee \$:** Fee \$ are earned by accounts (which own the contract) or customers (which are eligible members on the account's contract), depending upon the arrangement of the GPO. These fees typically have performance requirements, so the account or some of the customers might not earn a fee. The fee % is generally fixed. The fee is calculated using a UBC rebate contract format, but with claim data provided by a "Sales Data Pull". If the account earns a fee it is paid via check. If the customers earn fees, then payment is via a wholesaler credit issued to the customer's preferred wholesaler in the name of the customer. These accounts are typically commercial buying groups while the customers are institutions such as hospitals. This value is for a calendar quarter, with the fee **Date Paid** determining if a rebate participates in this quarter's calculation. If a sale is excluded from the ASP calculation, then the fee/rebate \$ associated with this sale must also be excluded.

- **SBC Rebate \$:** Rebate \$ are earned by accounts (which own the contract) or customers (which are eligible members on the account's contract), depending upon the arrangement of the GPO. These rebates typically have performance requirements, so the account or some of the customers might not earn a rebate. The rebate can be variable, depending upon performance. The rebate is calculated using a UBC rebate contract format, but with claim data provided by a "Sales Data Pull". If the account earns a rebate it is paid via check. If the customers earn rebates, then payment is via a wholesaler credit issued to the customer's preferred wholesaler in the name of the customer. These accounts are typically commercial buying groups while the customers are institutions such as hospitals. This value is for a calendar quarter, with the rebate **Date Paid** determining if a rebate participates in this quarter's calculation. If a sale is excluded from the ASP calculation, then the fee/rebate \$ associated with this sale must also be excluded.


MT 038704

AstraZeneca PharmaceuticalsCIA Average Sale Price Methodology

- **UBC Admin Fee \$:** Admin fee \$ are earned by accounts which own the managed care contract. These fees are typically not based upon performance requirements, and are generally at a flat %. The fee is calculated using a UBC rebate contract format, with claim data provided through ECP or manual entry. If the account earns a fee it is paid via check. The account is typically a PBM, mail-order, or HMO. A managed care contract can contain multiple fees and one rebate. "Flat Dollar" fees, which are fees/rebates paid off-invoice, must not be selected for this value. This value is for a calendar quarter, with the fee Date Paid determining if a fee participates in this quarter's calculation. U.S. Territories Sales are excluded.
- **UBC Performance Fee \$:** Fee \$ are earned by accounts which own the managed care contract. These fees typically have performance requirements, so the account might not earn a fee. The fee can be variable, depending upon performance. The fee is calculated using a UBC rebate contract format, with claim data provided through ECP or manual entry. If the account earns a fee it is paid via check. The account is typically a PBM, mail-order, or HMO. A managed care contract can contain multiple fees and one rebate. "Flat Dollar" fees, which are fees/rebates paid off-invoice, must not be selected for this value. This value is for a calendar quarter, with the fee Date Paid determining if a fee participates in this quarter's calculation. U.S. Territories Sales are excluded.
- **UBC Rebate \$:** Rebate \$ are earned by accounts which own the managed care contract. These rebates typically have performance requirements, so the account might not earn a rebate. The rebate can be variable, depending upon performance. The rebate is calculated using a UBC rebate contract format, with claim data provided through ECP or manual entry. If the account earns a rebate it is paid via check. A managed care contract can contain multiple fees and one rebate. "Flat Dollar" fees, which are fees/rebates paid off-invoice, must not be selected for this value. This value is for a calendar quarter, with the rebate Date Paid determining if a rebate participates in this quarter's calculation. U.S. Territories Sales are excluded.

MT 038705

EXHIBIT 7



January 06, 2005

Department of Public Health and Human Services
Attn: State Pharmacy Manager
1400 Broadway
P.O. Box 202951
Helena, MT 59620

Re: 3Q04 Average Sales Price
Labelers 00186 and 00310

Pleased be advised that in our letter dated November 11, 2004 containing our 3rd Quarter 2004 Average Sales Prices for Covered Products as identified in Appendix A in accordance with Section III (D)(2) of the June 2003 Corporate Integrity Agreement between AstraZeneca Pharmaceuticals LP and the Office of Inspector General (OIG), we realized that an incorrect second page was included in the transmission file. NDCs 00310037660 and 00310037732 on this page had preliminary prices.

Enclosed is the correct transmission file of our 3rd Quarter 2004 Average Sales Prices for the Covered Products identified in Appendix A.

If you have any questions or concerns relating to these Average Sales Prices, please contact Cindy Salfrank at (302) 886-5287 or myself at (302) 886-2268 and we will provide further details. We apologize for any inconvenience this oversight may have caused you.

Sincerely,

A handwritten signature in black ink, appearing to read "Esther L. Selvaggi".

Esther L. Selvaggi, CPA
Senior Manager, Government Pricing and Analytics
AstraZeneca Government Operations

Enclosures (1)

MT 038689

Managed Markets Business Group

AstraZeneca LP

1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437

www.astrazeneca-us.com

11/11/2007

00010 and 00310

SP	
00186001201	0.036563
00186001201	0.2117319
00186001201	0.1189330
00186001201	0.2254951
00186001201	0.4128008
00186001201	0.092861
00186001201	0.1082013
00186001201	0.2367494
00186001201	0.116913
00186001201	0.287043
00186001201	0.000000
00186001201	0.000000
00186001201	0.1005630
00186001201	0.1363373
00186001201	0.5501050
00186001201	0.000000
00186001201	0.1353346
00186001201	0.1110723
00186001201	0.000000
00186001201	0.067238
00186001201	0.1146896
00186001201	0.076924
00186001201	0.068487
00186001201	0.083985
00186001201	0.085261
00186001201	0.090130
00186001201	0.036400
00186001201	0.000000
00186001201	0.000000
00186001201	0.651312
00186001201	3.807620
00186001201	0.849306
00186001201	0.000000
00186001201	0.363082
00186001201	0.491451
00186001201	0.000000
00186001201	0.000000
00186001201	4.603363
00186001201	0.932003
00186001201	0.335095
00186001201	0.178684
00186001201	0.000000
00186001201	4.260182
00186001201	0.000000
00186001201	6.629582
00186001201	0.443483
00186001201	0.244385
00186001201	0.000000
00186001201	0.253767
00186001201	0.222838
00186001201	0.276422

MT 038690

11/11/2004

3Q04 ASP Data**Labelers 00186 and 00310**

NDC	ASP
00186026503	0.319828
00186027512	0.152807
00186027613	0.590903
00186027713	0.338101
00186027812	0.000000
00186027844	3.765645
00186027854	5.383066
00186190501	0.250821
00186190601	0.246977
00310004910	0.000000
00310010810	0.690886
00310032111	0.000000
00310032115	0.000000
00310032130	28.609909
00310032511	0.000000
00310032515	12.775900
00310032520	13.960914
00310037510	93.929683
00310037561	6.831386
00310037610	4.685271
00310037611	0.000000
00310037631	9.815421
00310037633	0.000000
00310037634	0.000000
00310037660	7.844979
00310037720	18.256348
00310037721	0.000000
00310037732	18.928207
00310037733	0.000000
00310037734	0.000000
00310037762	4.205903
00310037851	9.859923
00310037951	19.691096
00310072025	150.855201
00310072050	151.854311
00310095036	189.598855
00310095130	269.810273
00310096036	0.000000
00310096130	0.000000
00310328610	0.000000

MT 038691

EXHIBIT 8

AstraZeneca



May 12, 2005

Department of Public Health and Human Services
Attn: State Pharmacy Manager
1400 Broadway
P.O. Box 202951
Helena, MT 59620

Re: 1Q05 Average Sales Price
Labelers 00186 and 00310

In accordance with Section III (D)(2) of the June 2003 Corporate Integrity Agreement (CIA) between AstraZeneca Pharmaceuticals LP and the Office of Inspector General (OIG), enclosed are the 1st Quarter 2005 Average Sales Prices for Covered Products identified in Appendix A of the CIA which have been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through the issuance of regulations or written directives.

In an effort to keep our files current, we are requesting that you email any address changes and your contact person's telephone number (for Fed Ex deliveries) to:

Cindy.Salfrank@astrazeneca.com

If you have any questions or concerns relating to these Average Sales Prices, please contact Cindy Salfrank at (302) 886-5287 or me at (302) 886-3671 and we will provide further details.

Sincerely,

Christine McHenry
Senior Manager, Government Pricing and Analytics
AstraZeneca Government Operations

Enclosures (2)

RECEIVED

MAY 13 2005

**HEALTH RESOURCES
DIVISION**

MT 038951

ATTACHMENT 'A' CERTIFICATION FORM

CERTIFICATION

The undersigned, a high managerial agent of AstraZeneca Pharmaceuticals LP, hereby certifies that the attached average sale price information has been communicated to First DataBank and to the State Medicaid programs indicated below and that it has been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through regulations or written directives. I further acknowledge that the average sale prices so reported will be filed with and used in the administration of the Montana State Medicaid program(s).

Signed Christine McHenry
Christine McHenry

Title: Sr. Manager, Government Pricing and Analytics

Date: 5/12/05

MT 038952

NDC	PKG ASP
00186011001	1.55
00186011201	5.90
00186011291	25.97
00186011401	7.05
00186011412	18.94
00186011491	30.16
00186011501	1.69
00186011512	9.19
00186011701	6.37
00186011712	22.61
00186011791	38.59
00186011801	Last Payable 12/31/04
00186011891	0.00
00186012001	2.04
00186012201	7.60
00186012212	24.43
00186012213	Last Payable 08/31/02
00186012291	33.98
00186012501	1.97
00186012512	Last Payable 04/30/03
00186013501	3.59
00186013701	6.68
00186014001	3.27
00186014501	3.16
00186015001	3.96
00186015501	4.03
00186016001	4.46
00186016601	Last Payable 12/31/04
00186016801	Last Payable 05/31/04
00186016901	0.00
00186021003	12.48
00186021203	76.83
00186021503	18.29
00186022503	0.00
00186023003	17.36
00186023203	21.39
00186024002	0.00
00186024012	0.00
00186024044	20.26
00186024113	16.47
00186024213	16.82
00186024312	9.64
00186024412	0.00
00186024444	21.14
00186024502	0.00
00186024554	30.80
00186025002	37.69
00186025502	32.81
00186025592	Last Payable 02/01/04
00186026002	39.26
00186026092	0.00
00186026502	43.64

MT 038953

PRIVILEGED AND CONFIDENTIAL

Page 1 of 2

Contacts: Cindy Salfrank (302) 886-5287
Christine McHenry (302) 886-3671

NDC	PKG ASP
00186026503	16.97
00186027512	7.08
00186027613	11.33
00186027713	16.94
00186027812	0.00
00186027844	16.71
00186027854	0.00
00186190501	721.23
00186190601	1,423.88
00310004910	0.00
00310010810	35.56
00310032111	Last Payable 06/01/04
00310032115	0.00
00310032130	360.58
00310032511	Last Payable 11/30/04
00310032515	Last Payable 06/01/04
00310032520	173.21
00310037510	0.00
00310037561	0.00
00310037610	92.09
00310037611	0.00
00310037631	0.00
00310037633	0.00
00310037634	0.00
00310037660	0.00
00310037720	197.97
00310037721	0.00
00310037732	0.00
00310037733	0.00
00310037734	0.00
00310037762	0.00
00310037851	277.86
00310037951	557.50
00310072025	764.40
00310072050	767.79
00310095036	211.08
00310095130	485.49
00310096036	0.00
00310096130	0.00
00310328610	0.00

MT 038954

EXHIBIT 9

AstraZeneca 

August 11, 2005

Department of Public Health and Human Services
Attn: State Pharmacy Manager
1400 Broadway
P.O. Box 202951
Helena, MT 59601

RECEIVED
AUG 15 2005
HEALTH RESOURCES
DIVISION

Re: 2Q05 Average Sales Price
Labelers 00186 and 00310

In accordance with Section III (D)(2) of the June 2003 Corporate Integrity Agreement (CIA) between AstraZeneca Pharmaceuticals LP and the Office of Inspector General (OIG), enclosed are the 2nd Quarter 2005 Average Sales Prices for Covered Products identified in Appendix A of the CIA which have been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through the issuance of regulations or written directives.

In an effort to keep our files current, we are requesting that you email any address changes and your contact person's telephone number (for Fed Ex deliveries) to:

Ryan.Bruce@astrazeneca.com

If you have any questions or concerns relating to these Average Sales Prices, please contact Ryan Bruce at (302) 886-3956 or me at (302) 886-3671 and we will provide further details.

Sincerely,



Christine McHenry
Senior Manager, Government Pricing and Analytics
AstraZeneca Government Operations

Enclosures (2)

MT 038955

AstraZeneca LP
1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437

Tel 302 886 3000
www.astrazeneca-us.com

ATTACHMENT 'A' CERTIFICATION FORM

CERTIFICATION

The undersigned, a high managerial agent of AstraZeneca Pharmaceuticals LP, hereby certifies that the attached average sale price information has been communicated to First DataBank and to the State Medicaid programs indicated below and that it has been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through regulations or written directives. I further acknowledge that the average sale prices so reported will be filed with and used in the administration of the Montana State Medicaid program(s).

Signed Christine McHenry
Christine McHenry

Title: Sr. Manager, Government Pricing and Analytics

Date: 8/10/05

MT 038956

$$\frac{(\text{Accounts Receivable } \$ - \text{Exempt Sales } \$_{\text{SMOOTHED}} - \text{Price Concession } \$_{\text{SMOOTHED}})}{(\text{Accounts Receivable Units} - \text{Exempt Sales Units}_{\text{SMOOTHED}}) * \text{Units Per Package}}$$

For the Total Sales and Total Units basis in the smoothing methodology, AstraZeneca utilizes direct non-contracted transactions. This provides a consistent and appropriate basis for smoothing the price concession components of the calculation. Steps followed in the smoothing methodology are listed below:

- Step 1 in the price concession methodology is to calculate two totals as follows [2Q 2005 ASP calculation example]:
 - **Exempt Sales \$_{3Q 2004-2Q 2005} = (Chargeback Sales_{3Q 2004-2Q 2005} @ WAC \$) * 0.98**
 - **Price Concessions \$_{3Q 2004-2Q 2005} = Accounts Receivable Price Concessions \$_{3Q 2004-2Q 2005} + Chargeback Discounts Price Concessions \$_{3Q 2004-2Q 2005} + Managed Care Discount Price Concessions \$_{3Q 2004-2Q 2005}**
- Step 2 is to calculate two ratios as follows:
 - **Exempt Sales Ratio_{2Q 2005} = Exempt Sales \$_{3Q 2004-2Q 2005} / Direct Non Contracted Sales \$_{3Q 2004-2Q 2005}**
 - **Price Concession Ratio_{2Q 2005} = Price Concession \$_{3Q 2004-2Q 2005} / Direct Non Contracted Sales \$_{3Q 2004-2Q 2005}**
- Step 3 is to apply the two ratios against the current quarter's direct non-contracted sales/units as follows:
 - **Smoothed Exempt Sales \$_{2Q 2005} = Direct Non-Contracted Sales \$_{2Q 2005} * Exempt Sales Ratio_{2Q 2005}**
 - **Smoothed Exempt Sales Units_{2Q 2005} = Direct Non-Contracted Units_{2Q 2005} * Exempt Sales Ratio_{2Q 2005}**
 - **Smoothed Price Concession \$_{2Q 2005} = Direct Non-Contracted Sales \$_{2Q 2005} * Price Concession Ratio_{2Q 2005}**
- Step 4 is to calculate the ASP with the smoothed exempt sales and smoothed price concessions as follows:

$$\text{Average Sale Price}_{2Q 2005} =$$

$$\frac{(\text{Accounts Receivable } \$_{2Q 2005} - \text{Smoothed Exempt Sales } \$_{2Q 2005} - \text{Smoothed Price Concession } \$_{2Q 2005})}{(\text{Accounts Receivable Units}_{2Q 2005} - \text{Smoothed Exempt Sales Units}_{2Q 2005}) * \text{Units Per Pkg}}$$

MT 038957

Labelers 00186 and 00310

NDC	PKG ASP
00186011001	1.54
00186011201	5.76
00186011291	25.72
00186011401	6.83
00186011412	18.25
00186011491	30.56
00186011501	1.61
00186011512	8.33
00186011701	6.34
00186011712	22.40
00186011791	38.80
00186011801	Last Payable 12/31/04
00186011891	Last Payable 2/28/05
00186012001	2.00
00186012201	7.08
00186012212	23.69
00186012213	Last Payable 8/31/02
00186012291	34.33
00186012501	1.90
00186012512	Last Payable 4/30/03
00186013501	3.58
00186013701	6.39
00186014001	3.15
00186014501	3.24
00186015001	3.97
00186015501	4.07
00186016001	4.55
00186016601	Last Payable 12/31/04
00186016801	Last Payable 5/31/04
00186016901	0.00
00186021003	12.06
00186021203	76.70
00186021503	18.38
00186022503	Last Payable 9/30/03
00186023003	16.53
00186023203	20.13
00186024002	0.00
00186024012	0.00
00186024044	18.81
00186024113	16.38
00186024213	16.22
00186024312	9.61
00186024412	Last Payable 3/31/05
00186024444	19.26
00186024502	0.00
00186024554	30.27
00186025002	36.34
00186025502	31.34
00186025592	Last Payable 2/1/04
00186026002	40.27
00186026092	0.00
00186026502	44.77

MT 038958

2Q05 ASP Data**Labelers 00186 and 00310**

NDC	PKG ASP
00186026503	17.42
00186027512	6.83
00186027613	10.86
00186027713	16.10
00186027812	0.00
00186027844	16.16
00186027854	0.00
00186190501	725.02
00186190601	1,459.14
00186602001	416.50
00186604001	830.57
00310004910	0.00
00310010810	36.91
00310032111	Last Payable 6/1/04
00310032115	0.00
00310032130	369.25
00310032511	Last Payable 11/30/04
00310032515	Last Payable 6/1/04
00310032520	193.09
00310037510	0.00
00310037561	0.00
00310037610	95.38
00310037611	0.00
00310037631	0.00
00310037633	0.00
00310037634	0.00
00310037660	0.00
00310037720	200.29
00310037721	0.00
00310037732	0.00
00310037733	0.00
00310037734	0.00
00310037762	0.00
00310037851	283.61
00310037951	567.81
00310072025	764.54
00310072050	767.93
00310095036	208.33
00310095130	445.17
00310096036	0.00
00310096130	0.00
00310328610	0.00

MT 038959

EXHIBIT 10



November 10, 2005

Department of Public Health and Human Services
Attn: State Pharmacy Manager
1400 Broadway
P.O. Box 202951
Helena, MT 59601

RECEIVED

NOV 15 2005

HEALTH RESOURCES
DIVISION

Re: 3Q05 Average Sales Price
Labelers 00186 and 00310

In accordance with Section III (D)(2) of the June 2003 Corporate Integrity Agreement (CIA) between AstraZeneca Pharmaceuticals LP and the Office of Inspector General (OIG), enclosed are the 3rd Quarter 2005 Average Sales Prices for Covered Products identified in Appendix A of the CIA which have been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through the issuance of regulations or written directives.

In an effort to keep our files current, we are requesting that you email any address changes and your contact person's telephone number (for Fed Ex deliveries) to:

Ryan.Bruce@astrazeneca.com

If you have any questions or concerns relating to these Average Sales Prices, please contact Ryan Bruce at (302) 886-3956 or me at (302) 886-3671 and we will provide further details.

Sincerely,

A handwritten signature in cursive script, appearing to read "Joseph Myer".

Joseph Myer,
Senior Manager, Government Pricing and Analytics
AstraZeneca Government Operations

Enclosures (2)

MT 037983

ATTACHMENT 'A' CERTIFICATION FORM

CERTIFICATION

The undersigned, a high managerial agent of AstraZeneca Pharmaceuticals LP, hereby certifies that the attached average sale price information has been communicated to First DataBank and to the State Medicaid programs indicated below and that it has been calculated in accordance with the requirements of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, as they may be refined by the Secretary of the Department of Health and Human Services through regulations or written directives. I further acknowledge that the average sale prices so reported will be filed with and used in the administration of the Montana State Medicaid program(s).

Signed Joseph Myer
Joseph Myer

Title: Sr. Manager, Government Pricing and Analytics

Date: 11/10/05

MT 037984

3Q2005 Smoothed Calculation

$$\frac{(\text{Accounts Receivable } \$ - \text{Exempt Sales } \$_{\text{SMOOTHED}} - \text{Price Concession } \$_{\text{SMOOTHED}})}{(\text{Accounts Receivable Units} - \text{Exempt Sales Units}_{\text{SMOOTHED}}) * \text{Units Per Package}}$$

For the Total Sales and Total Units basis in the smoothing methodology, AstraZeneca utilizes direct non-contracted transactions. This provides a consistent and appropriate basis for smoothing the price concession components of the calculation. Steps followed in the smoothing methodology are listed below:

- Step 1 in the price concession methodology is to calculate two totals as follows [3Q 2005 ASP calculation example]:
 - **Exempt Sales \$_{4Q 2004-3Q 2005} = (Chargeback Sales_{4Q 2004-3Q 2005} @ WAC \$) * 0.98**
 - **Price Concessions \$_{4Q 2004-3Q 2005} = Accounts Receivable Price Concessions \$_{4Q 2004-3Q 2005} + Chargeback Discounts Price Concessions \$_{4Q 2004-3Q 2005} + Managed Care Discount Price Concessions \$_{4Q 2004-3Q 2005}**
- Step 2 is to calculate two ratios as follows:
 - **Exempt Sales Ratio_{3Q 2005} = Exempt Sales \$_{4Q 2004-3Q 2005} / Direct Non Contracted Sales \$_{4Q 2004-3Q 2005}**
 - **Price Concession Ratio_{3Q 2005} = Price Concession \$_{4Q 2004-3Q 2005} / Direct Non Contracted Sales \$_{4Q 2004-3Q 2005}**
- Step 3 is to apply the two ratios against the current quarter's direct non-contracted sales/units as follows:
 - **Smoothed Exempt Sales \$_{3Q 2005} = Direct Non-Contracted Sales \$_{3Q 2005} * Exempt Sales Ratio_{3Q 2005}**
 - **Smoothed Exempt Sales Units_{3Q 2005} = Direct Non-Contracted Units_{3Q 2005} * Exempt Sales Ratio_{3Q 2005}**
 - **Smoothed Price Concession \$_{3Q 2005} = Direct Non-Contracted Sales \$_{3Q 2005} * Price Concession Ratio_{3Q 2005}**
- Step 4 is to calculate the ASP with the smoothed exempt sales and smoothed price concessions as follows:

$$\text{Average Sale Price}_{3Q 2005} =$$

$$\frac{(\text{Accounts Receivable } \$_{3Q 2005} - \text{Smoothed Exempt Sales } \$_{3Q 2005} - \text{Smoothed Price Concession } \$_{3Q 2005})}{(\text{Accounts Receivable Units}_{3Q 2005} - \text{Smoothed Exempt Sales Units}_{3Q 2005}) * \text{Units Per Pkg}}$$

MT 037985

11/10/2005

3Q05 ASP Data**Labelers 00186 and 00310**

NDC	PKG ASP
00186011001	1.37
00186011201	5.05
00186011291	29.79
00186011401	5.90
00186011412	15.64
00186011491	27.40
00186011501	1.48
00186011512	7.68
00186011701	5.48
00186011712	21.81
00186011791	35.99
00186012001	1.86
00186012201	5.48
00186012212	20.70
00186012291	28.29
00186012501	1.64
00186013501	3.51
00186013701	5.62
00186014001	2.71
00186014501	3.16
00186015001	3.86
00186015501	4.07
00186016001	4.64
00186021003	11.08
00186021203	70.03
00186021503	18.17
00186023003	13.74
00186023203	17.53
00186024044	15.57
00186024113	13.34
00186024213	14.88
00186024312	9.47
00186024444	16.30
00186024554	28.84
00186025002	31.09
00186025502	27.39
00186026002	41.40
00186026092	0.00
00186026502	42.98
00186026503	17.31
00186027512	6.26
00186027613	9.95
00186027713	14.28
00186027844	15.10
00186190501	661.06
00186190601	1,406.74
00186602001	301.27
00186604001	481.61
00310004910	0.00
00310010810	36.40
00310032130	365.41
00310032520	183.88

MT 037986

3Q05 ASP Data

11/10/2005

Labelers 00186 and 00310

NDC	PKG ASP
00310037510	0.00
00310037561	0.00
00310037610	0.00
00310037611	0.00
00310037631	0.00
00310037633	0.00
00310037634	0.00
00310037660	0.00
00310037720	0.00
00310037732	0.00
00310037733	0.00
00310037734	0.00
00310037762	0.00
00310037851	286.23
00310037951	570.87
00310072025	764.76
00310072050	768.15
00310095036	212.71
00310095130	526.81
00310096036	0.00
00310096130	0.00
00310328610	0.00

MT 037987

ADDRESS CHANGE FOR LABELER 64376 and 67887

3550 NW 126TH AVENUE
CORAL SPRINGS, FL 33065

PH: 954-346-8810
FAX: 954-346-8832

Please Change Your Records Accordingly

MT 037988